Optimizing Novel Therapies and Surgery in Ear...

AMERICAN SOCIETY OF CLINICAL ONCOLOGY (ASCO)

Up next

'No Margin for Error': What to Know Before Implementing AI in Clinical Practice

Dr. Monty Pal and Dr. Arturo Loaiza-Bonilla discuss the institutional risks in the use of artificial intelligence (AI) in clinical practice and how overreliance on AI could erode essential skills. They also highlight practical approaches, including routine "AI-off" drills, to hel ... Show more

. 18min 20sec

Groundbreaking Results Shift Treatment Paradigm in High-Risk Smoldering Multiple Myeloma

Dr. Monty Pal speaks with internationally acclaimed hematologists Dr. Vincent Rajkumar and Dr. Saad Usmani about the AQUILA trial in high-risk smoldering multiple myeloma, as well as advances in CAR-T and other evolving treatment strategies in the myeloma space. TRANSCRIPT Dr. Mo ... Show more

. 19min 38sec

Recommended Episodes

Therapy for Stage IV NSCLC With Driver Alterations: ASCO Living Guideline Update 2024.1

ASCO Guidelines

Dr. Jyoti Patel discusses the latest update to the stage IV NSCLC with driver alterations living guideline, specifically for patients with EGFR or ROS1 alterations. She shares the latest recommendations based on recently published evidence, such as the FLAURA2, MARIPOSA-2, and TR ... Show more

. 12min 24sec

Systemic Therapy for SCLC: ASCO-OH (CCO) Guideline

ASCO Guidelines

Dr. Greg Kalemkerian joins us on the ASCO Guideline Podcast to discuss the newest ASCO – Ontario Health (Cancer Care Ontario) Guideline on systemic therapy for small-cell lung cancer (SCLC). He reviews the evidence-based recommendations from the panel, including guidance on syste ... Show more

. 27min 13sec

Mismatch Repair and Microsatellite Instability Testing for Immune Checkpoint Inhibitor Therapy: ASCO Endorsement of CAP Guideline

ASCO Guidelines

Dr. Praveen Vikas, Dr. Tyler Johnson, and Dr. Russell Broaddus present the ASCO endorsement of the Mismatch Repair and Microsatellite Instability Testing for Immune Checkpoint Inhibitor Therapy: Guideline From the College of American Pathologists in Collaboration With the Associa ... Show more

. 16min 31sec

Endocrine and Targeted Therapy for HR-Positive, HER2-Negative Metastatic Breast Cancer – Capivasertib-Fulvestrant: Rapid Guideline Update

ASCO Guidelines

Dr. Angela DeMichele, Dr. Lynn Henry, and Dr. Harold Burstein present the latest breast cancer rapid recommendation update impacting two ASCO guidelines. This update focuses on the new option, capivasertib plus fulvestrant, for patients with hormone receptor-positive, HER2-negati ... Show more

. 14min 9sec